A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates

Enyo Pharma18 sites in 4 countries26 target enrollmentMay 12, 2020

ConditionsHepatitis B, Chronic

InterventionsEYP001a Nucleotide analogue (Entecavir or Tenofovir Disoproxil)Placebo

Overview

Phase: Phase 2
Intervention: EYP001a
Conditions: Hepatitis B, Chronic
Sponsor: Enyo Pharma
Enrollment: 26
Locations: 18
Primary Endpoint: HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment
Status: Terminated
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a prospective, multi-centre, randomized, double-blind, placebo-controlled, Phase 2a experimental study of oral FXR modulator EYP001a/placebo combined with NAs in virologically suppressed CHB patients to improve functional cure rates.

Detailed Description

A total of 49 eligible patients will be enrolled and randomized at approximately 14 study sites. Patients will be randomized prior to study drug (EYP001a or placebo and NA) administration on Day 1 in the ratio of 3:1 into 2 arms: * Experimental Arm: EYP001a Dose A QD + NA daily (37 patients) * Control Arm: Placebo + NA daily (12 patients) The maximum total engagement duration for eligible patients in this study is up to 370 days: 90 days screening, 112 days (16 weeks) treatment period and 168 days (24 weeks) follow-up. Patients enrolled in the study will be assessed as outpatients. Patient screening will occur no more than 90 days prior to the Day 1 visit. Eligible patients will undergo further assessments on Day 1 to qualify for study drug administration on Day 1. The visits during the study are planned as below: * Screening visit: 12 weeks (90 days) * 16 weeks treatment period: * Treatment Visit 1 (Week 1 \[Day 1\]) * Treatment Visit 2 (Week 2 \[Day 14 ±3 days\]) * Treatment Visit 3 (Week 4 \[Day 28 ±3 days\]) * Treatment Visit 4 (Week 6 \[Day 42 ±3 days\]) * Treatment Visit 5 (Week 8 \[Day 56 ±3 days\]) * Treatment Visit 6 (Week 10 \[Day 70 ± 3 days\]) * Treatment Visit 7 (Week 12 \[Day 84 ± 3 days\]) * Treatment Visit 8 (Week 14 \[Day 98 ± 3 days\]) * Treatment Visit 9 (Week 16 \[Day 112±3 days\]) * 24 weeks safety follow-up period: * Follow-up Visit 1 (Week 20 \[Day 140 ±7 days\]) * Follow-up Visit 2 (Week 28 \[Day 196 ±7 days\]) * Follow-up Visit 3 (Week 40 \[Day 280 ±7 days\]) Note: during follow-up patients are kept on NA until the end of the trial: Week 40 (consolidation Phase).

Registry

clinicaltrials.gov

Start Date

May 12, 2020

End Date

November 25, 2021

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Enyo Pharma

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Are on stable NA therapy at least 12 months from the screening date (ETV or TDF)
•Has virally suppressed CHB:
•HBV DNA \<LLOQ and serum HBsAg \>100 IU/mL
•Has liver imaging to screen for hepatocellular carcinoma or concomitant pancreaticobiliary disease either in the prior 6 months or at screening.
•Is not of childbearing potential or, if of childbearing potential, is not pregnant as confirmed by a negative serum human chorionic gonadotropin test at screening and is not planning a pregnancy during the course of the study.

Exclusion Criteria

•Is an employee of a contract research organization (CRO), vendor, or Sponsor involved with this study.
•Has known hepatocellular carcinoma or pancreaticobiliary disease.
•Neutropenia (defined by two confirmed values within screening period of \<1500/μL).
•Has Gilbert syndrome.
•Shows evidence of worsening liver function, defined as either a confirmed (two assessments at least 3 days apart) increase \>2 ULN ALT or AST or an increase of \>1.5 × first assessed value of TBL or associated with clinical signs or symptoms of liver impairment.
•Has known or suspected non-CHB liver disease
•History of cirrhosis or liver decompensation, including ascites, hepatic encephalopathy, or presence of oesophageal varices.
•Probable or possible F3 stage with a vibration controlled transient elastography (VCTE). Patients with normal baseline ALT and VCTE \>8.8 kPa are excluded. Patients with baseline ALT \>ULN (but \<2ULN per EC5) and who have VCTE \>10.5 kPa at baseline are excluded
•Has known history of alcohol abuse or daily heavy alcohol consumption
•Has clinically relevant immunosuppression, including, but not limited to, immunodeficiency conditions such as common variable hypogammaglobulinemia.